Human Herpesvirus 8

  • Celeste Lebbé
  • Camille Francès
Part of the Cancer Treatment and Research book series (CTAR, volume 146)

Abbreviations marked with a star are explained in the appended lexicon when they appear in the text for the first time.


Primary Effusion Lymphoma HHV8 Infection Lytic Replication Death Effector Domain Primary Effusion Lymphoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266(5192):1865–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Schulz TF. The pleiotropic effects of Kaposi’s sarcoma herpesvirus. J Pathol 2006; 208(2):187–98.PubMedCrossRefGoogle Scholar
  3. 3.
    Renne R, Lagunoff M, Zhong W, Ganem D. The size and conformation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 1996; 70(11):8151–4.PubMedGoogle Scholar
  4. 4.
    Orenstein JM, Alkan S, Blauvelt A, Jeang KT, Weinstein MD, Ganem D, et al. Visualization of human herpesvirus type 8 in Kaposi’s sarcoma by light and transmission electron microscopy. AIDS 1997; 11(5):F35–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, et al. Primary characterization of a herpesvirus agent associated with Kaposi’s sarcomae. J Virol 1996; 70(1):549–58.PubMedGoogle Scholar
  6. 6.
    Neipel F, Albrecht JC, Fleckenstein B. Cell-homologous genes in the Kaposi’s sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J Virol 1997; 71(6):4187–92.PubMedGoogle Scholar
  7. 7.
    Kajumbula H, Wallace RG, Zong JC, Hokello J, Sussman N, Simms S, et al. Ugandan Kaposi’s sarcoma-associated herpesvirus phylogeny: evidence for cross-ethnic transmission of viral subtypes. Intervirology 2006; 49(3):133–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Hayward GS. Human herpesvirus 8 latent-state gene expression and apoptosis in Kaposi’s sarcoma lesions. J Natl Cancer Inst 1999; 91(20):1705–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Nicholas J, Zong JC, Alcendor DJ, Ciufo DM, Poole LJ, Sarisky RT, et al. Novel organizational features, captured cellular genes, and strain variability within the genome of KSHV/HHV8. J Natl Cancer Inst Monogr 1998(23):79–88.Google Scholar
  10. 10.
    Blackbourn DJ, Lennette E, Klencke B, Moses A, Chandran B, Weinstein M, et al. The restricted cellular host range of human herpesvirus 8. AIDS 2000; 14(9):1123–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Renne R, Blackbourn D, Whitby D, Levy J, Ganem D. Limited transmission of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol 1998; 72(6):5182–8.PubMedGoogle Scholar
  12. 12.
    Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004; 36(7):683–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004; 36(7):687–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Blasig C, Zietz C, Haar B, Neipel F, Esser S, Brockmeyer NH, et al. Monocytes in Kaposi’s sarcoma lesions are productively infected by human herpesvirus 8. J Virol 1997; 71(10):7963–8.PubMedGoogle Scholar
  15. 15.
    Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, et al. Kaposi’s sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995; 1(12):1274–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Widmer IC, Erb P, Grob H, Itin P, Baumann M, Stalder A, et al. Human herpesvirus 8 oral shedding in HIV-infected men with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2006; 42(4):420–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Barozzi P, Bosco R, Vallerini D, Potenza L, Torelli G, Luppi M, et al. KSHV/HHV-8 infection of tubular epithelial cells in transplantation kidney. Transplantation 2006; 82(6):851–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Akula SM, Naranatt PP, Walia NS, Wang FZ, Fegley B, Chandran B. Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) infection of human fibroblast cells occurs through endocytosis. J Virol 2003; 77(14):7978–90.PubMedCrossRefGoogle Scholar
  19. 19.
    Lu C, Gordon GM, Chandran B, Nickoloff BJ, Foreman KE. Human herpesvirus 8 reactivation and human immunodeficiency virus type 1 gp120. Arch Pathol Lab Med 2002; 126(8):941–6.PubMedGoogle Scholar
  20. 20.
    Wang FZ, Akula SM, Pramod NP, Zeng L, Chandran B. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J Virol 2001; 75(16):7517–27.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaleeba JA, Berger EA. Kaposi’s sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science 2006; 311(5769):1921–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Veettil MV, Sharma-Walia N, Sadagopan S, Raghu H, Sivakumar R, Naranatt PP, et al. RhoA-GTPase facilitates entry of Kaposi’s sarcoma-associated herpesvirus into adherent target cells in a Src-dependent manner. J Virol 2006; 80(23):11432–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Foreman KE, Friborg J Jr, Kong WP, Woffendin C, Polverini PJ, Nickoloff BJ, et al. Propagation of a human herpesvirus from AIDS-associated Kaposi’s sarcoma. N Engl J Med 1997; 336(3):163–71.PubMedCrossRefGoogle Scholar
  24. 24.
    Lebbe C, de Cremoux P, Rybojad M, Costa da Cunha C, Morel P, Calvo F. Kaposi’s sarcoma and new herpesvirus. Lancet 1995; 345(8958):1180.PubMedCrossRefGoogle Scholar
  25. 25.
    Cannon JS, Ciufo D, Hawkins AL, Griffin CA, Borowitz MJ, Hayward GS, et al. A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi’s sarcoma herpesvirus-containing supernatant. J Virol 2000; 74(21):10187–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Vieira J, O’Hearn P, Kimball L, Chandran B, Corey L. Activation of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. J Virol 2001; 75(3):1378–86.PubMedCrossRefGoogle Scholar
  27. 27.
    Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Invest 2004; 113(1):124–36.PubMedGoogle Scholar
  28. 28.
    Kellam P, Boshoff C, Whitby D, Matthews S, Weiss RA, Talbot SJ. Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virol 1997; 1(1):19–29.PubMedGoogle Scholar
  29. 29.
    Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, et al. The 222- to 234-kilodalton latent nuclear protein (LNA) of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virol 1997; 71(8):5915–21.PubMedGoogle Scholar
  30. 30.
    Glenn M, Rainbow L, Aurade F, Davison A, Schulz TF. Identification of a spliced gene from Kaposi’s sarcoma-associated herpesvirus encoding a protein with similarities to latent membrane proteins 1 and 2A of Epstein–Barr virus. J Virol 1999; 73(8):6953–63.PubMedGoogle Scholar
  31. 31.
    Jenner RG, Alba MM, Boshoff C, Kellam P. Kaposi’s sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 2001; 75(2):891–902.PubMedCrossRefGoogle Scholar
  32. 32.
    Gradoville L, Gerlach J, Grogan E, Shedd D, Nikiforow S, Metroka C, et al. Kaposi’s sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J Virol 2000; 74(13):6207–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Lukac DM, Kirshner JR, Ganem D. Transcriptional activation by the product of open reading frame 50 of Kaposi’s sarcoma-associated herpesvirus is required for lytic viral reactivation in B cells. J Virol 1999; 73(11):9348–61.PubMedGoogle Scholar
  34. 34.
    Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, et al. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS Pathog 2007; 3(3): e44.PubMedCrossRefGoogle Scholar
  35. 35.
    Matsushima AY, Strauchen JA, Lee G, Scigliano E, Hale EE, Weisse MT, et al. Posttransplantation plasmacytic proliferations related to Kaposi’s sarcoma-associated herpesvirus. Am J Surg Pathol 1999; 23(11):1393–400.PubMedCrossRefGoogle Scholar
  36. 36.
    Du MQ, Diss TC, Liu H, Ye H, Hamoudi RA, Cabecadas J, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood 2002; 100(9):3415–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, et al. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med 2000; 343(19):1378–85.PubMedCrossRefGoogle Scholar
  38. 38.
    Adams PD. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 2001; 1471(3):M123–33.PubMedGoogle Scholar
  39. 39.
    Verschuren EW, Jones N, Evan GI. The cell cycle and how it is steered by Kaposi’s sarcoma-associated herpesvirus cyclin. J Gen Virol 2004; 85(Pt 6):1347–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol 2007; 312:101–36.PubMedCrossRefGoogle Scholar
  41. 41.
    Widmer I, Wernli M, Bachmann F, Gudat F, Cathomas G, Erb P. Differential expression of viral Bcl-2 encoded by Kaposi’s sarcoma-associated herpesvirus and human Bcl-2 in primary effusion lymphoma cells and Kaposi’s sarcoma lesions. J Virol 2002; 76(5):2551–6.PubMedCrossRefGoogle Scholar
  42. 42.
    Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999; 190(7):1025–32.PubMedCrossRefGoogle Scholar
  43. 43.
    Sturzl M, Hohenadl C, Zietz C, Castanos-Velez E, Wunderlich A, Ascherl G, et al. Expression of K13/v-FLIP gene of human herpesvirus 8 and apoptosis in Kaposi’s sarcoma spindle cells. J Natl Cancer Inst 1999; 91(20):1725–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Grossmann C, Podgrabinska S, Skobe M, Ganem D. Activation of NF-kappaB by the latent vFLIP gene of Kaposi’s sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J Virol 2006; 80(14):7179–85.PubMedCrossRefGoogle Scholar
  45. 45.
    Moore PS, Chang Y. Kaposi’s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol 2003; 57:609–39.PubMedCrossRefGoogle Scholar
  46. 46.
    Stine JT, Wood C, Hill M, Epp A, Raport CJ, Schweickart VL, et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 2000; 95(4):1151–7.PubMedGoogle Scholar
  47. 47.
    Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, et al. Angiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93(12):4034–43.PubMedGoogle Scholar
  48. 48.
    Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997; 385(6614):347–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, Moore PS, et al. Kaposi’s sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi’s sarcoma and malignant lymphoma. J Virol 1996; 70(11):8218–23.PubMedGoogle Scholar
  50. 50.
    Couty JP, Gershengorn MC. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8). Biol Cell 2004; 96(5):349–54.PubMedCrossRefGoogle Scholar
  51. 51.
    Guo HG, Sadowska M, Reid W, Tschachler E, Hayward G, Reitz M. Kaposi’s sarcoma-like tumors in a human herpesvirus 8 ORF74 transgenic mouse. J Virol 2003; 77(4):2631–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Coscoy L. Immune evasion by Kaposi’s sarcoma-associated herpesvirus. Nat Rev Immunol 2007; 7(5):391–401.PubMedCrossRefGoogle Scholar
  53. 53.
    Coscoy L, Ganem D. Kaposi’s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA 2000; 97(14):8051–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Coscoy L, Ganem D. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J Clin Invest 2001; 107(12):1599–606.PubMedCrossRefGoogle Scholar
  55. 55.
    Parsons CH, Adang LA, Overdevest J, O’Connor CM, Taylor JR Jr, Camerini D, et al. KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J Clin Invest 2006; 116(7):1963–73.PubMedCrossRefGoogle Scholar
  56. 56.
    Mutlu AD, Cavallin LE, Vincent L, Chiozzini C, Eroles P, Duran EM, et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi’s sarcoma. Cancer Cell 2007; 11(3):245–58.PubMedCrossRefGoogle Scholar
  57. 57.
    Sodhi A, Chaisuparat R, Hu J, Ramsdell AK, Manning BD, Sausville EA, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006; 10(2):133–43.PubMedCrossRefGoogle Scholar
  58. 58.
    Corchero JL, Mar EC, Spira TJ, Pellett PE, Inoue N. Comparison of serologic assays for detection of antibodies against human herpesvirus 8. Clin Diagn Lab Immunol 2001; 8(5):913–21.PubMedGoogle Scholar
  59. 59.
    Sarmati L. Serological testing for human herpesvirus 8. Herpes 2001; 8(3):76–9.PubMedGoogle Scholar
  60. 60.
    Schatz O, Monini P, Bugarini R, Neipel F, Schulz TF, Andreoni M, et al. Kaposi’s sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays. J Med Virol 2001; 65(1):123–32.PubMedCrossRefGoogle Scholar
  61. 61.
    Laney AS, Peters JS, Manzi SM, Kingsley LA, Chang Y, Moore PS. Use of a multiantigen detection algorithm for diagnosis of Kaposi’s sarcoma-associated herpesvirus infection. J Clin Microbiol 2006; 44(10):3734–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi’s sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117(4):858–63.PubMedCrossRefGoogle Scholar
  63. 63.
    Pellet C, Chevret S, Frances C, Euvrard S, Hurault M, Legendre C, et al. Prognostic value of quantitative Kaposi sarcoma-associated herpesvirus load in posttransplantation Kaposi sarcoma. J Infect Dis 2002; 186(1):110–3.PubMedCrossRefGoogle Scholar
  64. 64.
    Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, et al. Kaposi’s sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi’s sarcoma. J Invest Dermatol 2006; 126(3):621–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999; 96(8):4546–51.PubMedCrossRefGoogle Scholar
  66. 66.
    Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003; 17(12):1717–30.PubMedCrossRefGoogle Scholar
  67. 67.
    Plancoulaine S, Gessain A. Epidemiological aspects of human herpesvirus 8 infection and of Kaposi’s sarcoma. Med Mal Infect 2005; 35(5):314–21.PubMedCrossRefGoogle Scholar
  68. 68.
    Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, et al. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355(13):1331–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Moore PS, Chang Y, Jaffe HW. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2007; 356(1):88; author reply 89.PubMedGoogle Scholar
  70. 70.
    Barozzi P, Luppi M, Facchetti F, Mecucci C, Alu M, Sarid R, et al. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med 2003; 9(5): 554–61.PubMedCrossRefGoogle Scholar
  71. 71.
    Luppi M, Barozzi P, Rasini V, Riva G, Re A, Rossi G, et al. Severe pancytopenia and hemophagocytosis after HHV-8 primary infection in a renal transplant patient successfully treated with foscarnet. Transplantation 2002; 74(1):131–2.PubMedCrossRefGoogle Scholar
  72. 72.
    Regamey N, Tamm M, Binet I, Thiel G, Erb P, Cathomas G. Transplantation-associated Kaposi’s sarcoma: herpesvirus 8 transmission through renal allografts. Transplant Proc 1999; 31(1–2):922–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Plancoulaine S, Abel L, van Beveren M, Tregouet DA, Joubert M, Tortevoye P, et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet 2000; 356(9235):1062–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Coluzzi M, Manno D, Guzzinati S, Tognazzo S, Zambon P, Arca B, et al. The bloodsucking arthropod bite as possible cofactor in the transmission of human herpesvirus-8 infection and in the expression of Kaposi’s sarcoma disease. Parassitologia (Rome) 2002; 44(1–2): 123–9.Google Scholar
  75. 75.
    Kouri V, Marini A, Nambiar S, Rodriguez ME, Capo V, Resik S, et al. Nearly identical strains of human herpesvirus 8 in couples discordant for Kaposi’s sarcoma. AIDS 2007; 21(6):765–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063–70.PubMedCrossRefGoogle Scholar
  77. 77.
    Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99(9):2082–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi’s sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17(5):447–55.PubMedCrossRefGoogle Scholar
  79. 79.
    Crum-Cianflone NF, Wallace MR, Looney D. Successful secondary prophylaxis for primary effusion lymphoma with human herpesvirus 8 therapy. AIDS 2006; 20(11):1567–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Curreli F, Friedman-Kien AE, Flore O. Glycyrrhizic acid alters Kaposi sarcoma-associated herpesvirus latency, triggering p53-mediated apoptosis in transformed B lymphocytes. J Clin Invest 2005; 115(3):642–52.PubMedGoogle Scholar
  81. 81.
    Moses AV, Jarvis MA, Raggo C, et al. Kaposi’s sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. J Virol 2002; 76:8383–99.PubMedCrossRefGoogle Scholar
  82. 82.
    Lebbe C, Euvrard S, Barrou B, Pouteil-Noble C, Garnier JL, Glotz D, et al. Sirolimus conversion for patients with posttransplant Kaposi’s sarcoma. Am J Transplant 2006; 6(9):2164–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005; 352(13):1317–23.PubMedCrossRefGoogle Scholar
  84. 84.
    Guihot A, Dupin N, Marcelin AG, Gorin I, Bedin AS, Bossi P, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 2006; 194(8):1078–88.PubMedCrossRefGoogle Scholar
  85. 85.
    Lambert M, Gannage M, Karras A, Abel M, Legendre C, Kerob D, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood 2006; 108(12):3871–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Celeste Lebbé
    • 1
  • Camille Francès
    • 2
  1. 1.Department of DermatologyAPHP Hospital Saint LouisParisFrance
  2. 2.Department of DermatologyAPHP Hospital Tenon ParisParisFrance

Personalised recommendations